MediumEndocrinologyType 2 diabetes with cardiovascular diseaseau-amcau-racp
A 63-year-old man with type 2 diabetes and established coronary artery disease (previous NSTEMI) has HbA1c 7.8% (62 mmol/mol) despite maximally tolerated metformin. His eGFR is 55 mL/min/1.73 m² and he has microalbuminuria. According to contemporary Australian recommendations, which additional agent class is preferred for cardiovascular and renal risk reduction?